Advances in Aggressive Lymphoma From the 2017 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2017 American Society of Hematology Annual Meeting and Exposition • December 9-12, 2017 • Atlanta, Georgia Long-Term Follow-Up […]

Highlights in Lymphoma From the 2017 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2017 American Society of Hematology Annual Meeting and Exposition • December 9-12, 2017 • Atlanta, Georgia Brentuximab Vedotin Plus […]

Hem/Onc News

Axicabtagene, Second CAR T-Cell Therapy, Approved in Lymphoma The US Food and Drug Administration (FDA) approved the T-cell therapy axicabtagene ciloleucel (Yescarta, Kite) on October 18 […]

Hem/Onc News

Abemaciclib Approved in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer On September 28, the US Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Lilly) as a […]

Highlights in Lymphoma From the 2016 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2016 American Society of Hematology Annual Meeting and Exposition December 3-6, 2016 • San Diego, California PLUS Meeting Abstract […]

Highlights in Lymphoma From the 2015 American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 2015 American Society of Hematology Annual Meeting and Exposition • December 5-8, 2015 • Orlando, Florida Special Reporting on: […]

Castleman Disease in the 21st Century: An Update on Diagnosis, Assessment, and Therapy

Abstract: Castleman disease (CD) is a nonclonal lymphoproliferative disorder that can affect single lymph node stations or, alternatively, can be generalized. Interleukin 6 (IL6) plays a pivotal role in the pathophysiology of CD. Human herpesvirus 8 (HHV8), which encodes a viral homolog of IL6, is the driving force in HIV-positive patients. The role of HHV8 in HIV-negative CD is controversial. Historically, the prognosis of patients with generalized or multicentric CD has been thought to be poor. However, CD responds extremely well to monoclonal antibodies directed at the IL6 receptor or IL6 itself, and in general, the long-term outcome of HIV-negative CD is excellent. Important strides forward have also been made in the management of HIV-positive CD.